Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

European School of Haematology (ESH) meeting: International Conference on Acute Lymphoblastic Leukaemia 2019 (ICALL) /
MLL-rearranged acute lymphoblastic leukaemia

17th - 19th May 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 24.05.19
Views: 1168
Rating:

Dr Pablo Menéndez - Josep Carreras Leukemia Research Institute, Barcelona, Spain

Dr Pablo Menéndez talks to ecancer at the European School of Haematology (ESH) meeting: International Conference on Acute Lymphoblastic Leukaemia about the MLL rearrangement in paediatric acute lymphoblastic leukaemia (ALL).

He describes the origin of this disease, including the generation of this translocation using in vivo methods and its associated consequences.

Dr Menéndez also discusses how these mutations can be targeted both before and after relapse and how the genetic differences between ALL subtypes.

He concludes by stating the possible therapeutic approaches for this disease - including the inhibition of NG2 to cause a delay in relapse.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation